Aug 11, 2022 – Our 20th Japanese profile has just been uploaded
The National Cancer Registry (NCR) commenced operations in January 2016. Accurate nationwide data obtained from NCR contribute to the planning and evaluation of cancer control in Japan. This database is utilized in evaluating the quality of medical care for cancer patients, in assessing the accuracy of cancer screening, and in follow-up surveys in nationwide cohort studies.
National Cancer Registry (Japan)
Database Contact Data
Please complete the contact form (in Japanese or English) at - https://reg18.smp.ne.jp/regist/is?SMPFORM=ndqe-lfogsa-3b8c6f3d580c85ee376b1c4fd94627fa
Alternate Contact
N/A
References of Studies Using/Describing Database
1. Muramatsu S, Ogura K, Morizane C, Satake T, Iwata S, Kobayashi E, Higashi T, Toda Y, Takemori T, Kondo H, Kawai A. Epidemiology and prognosis of malignant peripheral nerve sheath tumor (MPNST) in Japan: A population-based analysis using the national cancer registry. J Orthop Sci. 2025 Oct 9:S0949-2658(25)00278-7.
2. Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Takemori T, Kondo H, Kobayashi E, Arakawa A, Ogawa C, Katoh Y, Higashi T, Kawai A. Incidence and age- and site-specific characteristics of osteosarcoma: a population-based study using National Cancer Registry 2016-2019. Jpn J Clin Oncol. 2025 Sep 5;55(9):1037-1045.
3. Hirano H, Naito Y, Nishida T, Higashi T, Satake T, Morizane C, Kawai A. Epidemiologic Features and Age-Related Differences in Management among Patients with Gastrointestinal Stromal Tumors in Japan: A National Cancer Registry Study. Cancer Res Commun. 2025 Jul 1;5(7):1235-1242.
4. Watari S, Ichikawa T, Takao S, Kurihara Y, Matsumi A, Tokunaga M, Kubota R, Kusumi N, Tsushima T. Improvements in the prognosis of patients with stage IV renal cancer according to the era of therapeutic agents: an analysis of National Cancer Registry data. Transl Androl Urol. 2025 Jun 30;14(6):1734-1741.
5. Gon Y, Zha L, Kawano T, Kudo H, Morishima T, Sasaki T, Miyashiro I, Mochizuki H, Sobue T. Specific Cardiovascular Mortality in Cancer Survivors: A Nationwide Population-Based Cohort Study in Japan. J Am Heart Assoc. 2025 May 20;14(10):e037965.
6. Kondo H, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Takemori T, Kobayashi E, Higashi T, Kawai A. Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry. Jpn J Clin Oncol. 2025 Apr 26;55(5):490-497.
7. Takemori T, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Kondo H, Kobayashi E, Higashi T, Kawai A. Incidence and site specific characteristics of angiosarcoma in Japan using a population-based national cancer registry from 2016 to 2019. Sci Rep. 2025 Mar 22;15(1):9960.
8. Muramatsu S, Ogura K, Morizane C, Satake T, Toda Y, Iwata S, Kobayashi E, Higashi T, Ikeuchi M, Kawai A. Statistics of Visceral Sarcoma in Japan: Report From the Population-Based National Cancer Registry (NCR) in Japan. J Surg Oncol. 2025 Feb;131(2):274-284.
9. Ogata D, Namikawa K, Nakano E, Fujimori M, Uchitomi Y, Higashi T, Satake T, Morizane C, Yamazaki N, Kawai A. Comprehensive epidemiology of melanoma at all sites: insights from Japan's National Cancer Registry, 2016-2017. Int J Clin Oncol. 2025 Feb;30(2):194-198.
10. Nakata K, Matsuda T, Hori M, Sugiyama H, Tabuchi K, Miyashiro I, Matsumoto K, Yoneda A, Takita J, Shimizu C, Katanoda K. Cancer incidence and type of treatment hospital among children, adolescents, and young adults in Japan, 2016-2018. Cancer Sci. 2023 Sep;114(9):3770-3782.
July 5, 2022: The Swedish Multiple Sclerosis Registry profile has just been added
Active since 2001, the Swedish MS Registry (SMSreg) is a government-funded quality register designed to ensure optimal health care for patients with multiple sclerosis (MS). All Swedish neurology departments are users and providers of data, and currently more than 14,000 patients with MS have been registered.
Swedish Multiple Sclerosis Registry (Sweden) **
Database Contact Data
Prof. Jan Hillert
Karolinska University Hospital
17176 Stockholm
SWEDEN
Email: jan.hillert@ki.se
Alternate Contact
1. Anna Cunningham (Multiple Sclerosis)
Email: anna.cunningham@regionstockholm.se
2. Email - info@neuroreg.se
References of Studies Using/Describing Database
1. Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, Hambraeus J, Axelsson M, Nimer FA, Sundström P, Gunnarsson M, Johansson R, Mellergård J, Rosenstein I, Ayad A, Sjöblom I, Risedal A, de Flon P, Gilland E, Lindeberg J, Shawket F, Piehl F, Lycke J. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022 Aug;21(8):693-703.
2. Spelman T, Forsberg L, McKay K, Glaser A, Hillert J. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. Mult Scler. 2022 Jun;28(7):1051-1059.
3. Manouchehrinia A, Kingwell E, Zhu F, Tremlett H, Hillert J, Ramanujam R. A multiple sclerosis disease progression measure based on cumulative disability. Mult Scler. 2021 Oct;27(12):1875-1883.
4. Landtblom AM, Berntsson SG, Boström I, Iacobaeus E. Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol Scand. 2021 Sep;144(3):229-235.
5. Hedström AK, Hillert J, Brenner N, Butt J, Waterboer T, Strid P, Kockum I, Olsson T, Alfredsson L. DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):717-722.
6. Stenberg E, Forsberg L, Hedström A, Hillert J, Näslund E. Bariatric and metabolic surgery in patients with morbid obesity and multiple sclerosis - a nationwide, matched cohort study. Surg Obes Relat Dis. 2021 Jun;17(6):1108-1114.
7. Kågström S, Fält A, Berglund A, Piehl F, Olsson T, Lycke J. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. Mult Scler Relat Disord. 2021 May;50:102842.
8. McKay KA, Friberg E, Razaz N, Alexanderson K, Hillert J. Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2021 Apr 1;78(4):478-482.
9. Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde R, Stawiarz L, Manouchehrinia A, Spelman T. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Front Neurol. 2021 Mar 17;12:647811.
10. Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021 Mar 16;96(11):e1574-e1584.
Cerner Enviza Cancerology (France) §
Database Contact Data
N/A
Alternate Contact
N/A
References of Studies Using/Describing Database
1. Weisel K, Wadlund AO, Gungor G, Dergarabetian E, Pacheco C, Masurkar N, Rodriguez-Otero P. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy. Eur J Haematol. 2022 Oct;109(4):388-397.
2. E. Manna, K. Kikuchi , H. Chalubert , I. Amri, P. Medina. BRAF mutation testing and results among French patients with solid tumours. Poster presented at ESMO 2020.
3. Bassila L, Medina P, Chalubert H. Trends in anti-emetic drug use in hematology-oncology based on Cancerology data in France. Poster presented at ISPOR US 2020.
4. Chabernaud H, Descoins S, Flinois A, Real-world studies in Onco-hematology: which parameter should be used to measure the efficacy of treatments. Poster presented at ISPOR EU 2019.
5. Medina P, Chalubert H, Pezic N, Wiegand J, Brihaye H, Spitzer M. PCN147 Epidemiologic burden of pulmonary metastasis in France. Value in Health. 2019 May 1;22:S84.
6. Colomer R, Hall P, Szkultecka-Debek M, Bondi RC, Flinois A, Auziere S, Le Cléac'h JY. Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC. Breast Cancer Res Treat. 2018 Feb;168(1):197-205.
7. Klein AB, Wang H, Shire N, Chalubert H, Alessandrini ER, Descoins S, Medina P. Treatment Patterns In Head & Neck Squamous Cell Cancer In France: Artiste Study on Cancerology Patient Charts. Value in Health. 2017 Oct 1;20(9):A419.
8. Chabernaud H, Bonnelye G, Flinois A, French physician sensitivity to and consideration of the costs of cancer treatment. Poster presented at ISPOR EU 2015.
9. Flinois A, Bonnelye G, Chabernaud H, Evolution of the number of patients treated for metastatic cancer between 2003 and 2013 in France. Poster presented at ISPOR EU 2015.
Jun 17, 2022: Our 370th profile is the Japan Nurses’ Health Study
Initiated in 2001, the Japan Nurses’ Health Study (JNHS) is a prospective cohort investigation of the effects of lifestyle and healthcare on women’s health.